Suggested remit: To appraise the clinical and cost effectiveness of lisocabtagene maraleucel within its marketing authorisation for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 3887

Provisional Schedule

Committee meeting 02 October 2024
Expected publication 11 December 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Bristol-Myers Squibb (Lisocabtagene maraleucel)
Others Department of Health and Social Care
  NHS England
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency for Equality
  Blood Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer52
  DKMS
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Kevin Kararwa Leukaemia Trust
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  WMUK
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Cutaneous Lymphoma Group
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (carboplatin, cisplatin, cytarabine, gemcitabine)
  Advanz Pharma (dexamethasone)
  Aspen (dexamethasone)
  Baxter Healthcare (ifosfamide)
  Cheplapharm Arzneimittel GmbH (etoposide)
  Glenmark Pharmaceuticals (dexamethasone)
  Hameln Pharma (dexamethasone)
  Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine)
  Jazz Pharmaceuticals UK (cytarabine)
  Martindale Pharma (dexamethasone)
  Napp Pharmaceuticals (rituximab)
  Panpharma UK (dexamethasone)
  Pfizer (cytarabine, rituximab)
  Roche Products (rituximab)
  Rosemont Pharmaceuticals (dexamethasone)
  Sun Pharmaceutical (gemcitabine)
  Synchrony Pharma (dexamethasone)
  Sandoz (cisplatin, rituximab)
  Thame Laboratories (dexamethasone)
  Wockhardt UK (dexamethasone)
General commentators All Wales Therapeutics & Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Group
  Cochrane UK
  Genomics England
  Institute of Cancer Research
  Leukaemia Busters
  Leukaemia UK
  Lymphoma Research Trust
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Institute High Grade Lymphoma Subgroup
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
04 March 2024 Invitation to participate
11 January 2024 - 08 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3887
11 January 2024 In progress. Scoping commencing
24 May 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
19 October 2021 Following information received from the company the timelines for this appraisal are currently to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.

For further information on our processes and methods, please see our CHTE processes and methods manual